Can a Two-Drug combo outsmart pancreatic cancer?
Disease control
Not yet recruiting
This early-stage trial tests an experimental oral drug called SNV1521, a PARP inhibitor, combined with the RAS-targeting medicine daraxonrasib in adults with pancreatic cancer that cannot be surgically removed or has spread. The main goals are to find safe and tolerable doses of …
Phase: PHASE1 • Sponsor: Synnovation Therapeutics, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC